Breast cancer is the most frequently diagnosed cancer in the United States of America, claiming over 42,000 lives each year.1 Numerous treatments have improved survival; however, aggressive subtypes, such as triple negative (TNBC) and epidermal growth factor receptor 2 (HER2)-positive breast cancer, are still challenging to treat and often deadly. Here, ERBB2 is linked to breast carcinoma.